Abciximab
Brand: ReoPro (US/EU) / Abcixirel (IN) / Abximab (IN) / Reopro (BD)
Antiplatelet
GP IIb/IIIa inhibitor (IV, monoclonal antibody)
Chemistry
| Molecular Formula | C6350H9812N1688O1992S44 |
| PubChem |
CID: 481101467 Open in PubChem |
Structure
Pharmacokinetics
| Half-life | 0.5 hours |
| Tmax | 0 h |
| Protein Binding | 100 % |
| Volume of Distribution | 0.04 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Very short plasma half-life, but prolonged platelet receptor binding → effect lasts 24–48 hours; used only IV during PCI. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Bleeding, thrombocytopenia, hypotension, allergic reactions
Contraindications:
Active internal bleeding, recent major surgery, severe thrombocytopenia, history of stroke
Precautions:
Monitor platelets; increased bleeding risk with heparin/other antiplatelets; avoid intramuscular injections post-administration